Anti-Atherosclerosis and Anti-Hyperlipidemia Functions of Terminalia catappa Fruit

Doris Tabansi1, Daniel Dahiru1, Ambrose Teru Patrick2,3

  • 1Department of Biochemistry, Faculty of Life Sciences, Modibbo Adama University of Technology, Yola 640101, Nigeria.

ACS Omega
|October 9, 2023
PubMed

Insights

Terminalia catappa fruit extracts show promise in reversing harmful lipid profiles in rats with diet-induced atherosclerosis. This natural approach may offer a safer alternative to synthetic drugs for treating atherosclerosis.

Area of Science:

  • Pharmacology and Toxicology
  • Natural Product Chemistry
  • Cardiovascular Research

Background:

  • Atherosclerosis is a silent, progressive disease driven by factors like diet, hyperlipidemia, and aging.
  • Current synthetic treatments for atherosclerosis carry significant risks, including myositis and renal failure.
  • Research is exploring natural compounds as safer alternatives for managing atherosclerosis.

Purpose of the Study:

  • To investigate the antiatherosclerotic and antihyperlipidemic potential of Terminalia catappa fruit extracts.
  • To test the hypothesis using a diet-induced atherosclerosis rat model.

Main Methods:

  • Wistar rats were induced with atherosclerosis using an atherogenic diet.
  • Phytochemical analysis of Terminalia catappa extracts was performed.
  • Key lipid profile markers (TC, TG, HDL) and liver/cardiac enzymes (AST, ALT, CK, LDH) were quantified.

Main Results:

  • Terminalia catappa extracts contained various bioactive compounds, including flavonoids, saponins, and phenols.
  • Atherogenic diet significantly increased lipid levels (TC, TG, LDL, VLDL) in rats.
  • Treatment with T. catappa extracts reversed the atherogenic lipid profile, reducing coronary risk and atherogenic indices while increasing the cardioprotective index.

Conclusions:

  • Terminalia catappa fruit extracts demonstrate significant antihyperlipidemic and antiatherosclerotic effects in a rat model.
  • The findings suggest that Terminalia catappa contains bioactive molecules with therapeutic potential for atherosclerosis treatment.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
681
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
541
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9